Caplight Directory>Companies>Vima Therapeutics-preview>Vimatx


Vima Therapeutics

Vima Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://vimatx.com/

Last Round

Series A

Mar 11, 2026

Total Funding Raised

$100M

Momentum Score

100 /100

Company Overview

Vima Therapeutics is a biotechnology company developing oral therapeutics designed for the treatment of movement disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B2C

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

dystonia therapymovement disorder therapyoral therapysmall molecule drugclinical-stage biotechCNS drug developmentfirst-in-class therapymuscarinic receptor modulatorneurology drug discoverytherapeutics development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vima Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vima Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMar 11, 2026
Series AMay 29, 2025
View all Funding Rounds

Key People

Founding team and executive leadership

Bernard Ravina

Chief Executive Officer

Executive Team

Vima Therapeutics Investors

Notable investors and investment history

InvestorRounds
Access IndustriesSeries A
Frazier Life SciencesSeries A
Canaan PartnersSeries A
Atlas VentureSeries A, Seed
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Monthly visitors increased 303% MoM, reaching 2.4K.

  • Apr 22, 2026

    Grew 29% QoQ from 17 to 22 employees.

View all signals

Vima Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vima Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vima Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range22
Year Founded2023
Last FundingMar 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.